Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
J Control Release. 2022 Aug;348:706-722. doi: 10.1016/j.jconrel.2022.06.026. Epub 2022 Jun 22.
Nanomedicine research has advanced dramatically in recent decades. Nonetheless, traditional nanomedicine faces significant obstacles such as the low concentration of the drug at target sites and accelerated removal of the drug from blood circulation. Various techniques of nanotechnology, including cell membrane coating, have been developed to address these challenges and to improve targeted distribution and redcue cell membrane-mediated immunogenicity. Recently, stem cell (SC) membranes, owing to their immunosuppressive and regenerative properties, have grabbed attention as attractive therapeutic carriers for targeting specific tissues or organs. Bioengineering strategies that combine synthetic nanoparticles (NPs) with SC membranes, because of their homing potential and tumor tropism, have recently received a lot of publicity. Several laboratory experiments and clinical trials have indicated that the benefits of SC-based technologies are mostly related to the effects of SC-derived exosomes (SC-Exos). Exosomes are known as nano-sized extracellular vehicles (EVs) that deliver particular bioactive molecules for cell-to-cell communication. In this regard, SC-derived exosome membranes have recently been employed to improve the therapeutic capability of engineered drug delivery vehicles. Most recently, for further enhancing NPs' functionality, a new coating approach has been offered that combines membranes from two separate cells. These hybrid membrane delivery vehicles have paved the way for the development of biocompatible, high-efficiency, biomimetic NPs with varying hybrid capabilities that can overcome the drawbacks of present NP-based treatment techniques. This review explores stem cell membranes, SC-Exos, and hybrid SC-camouflaged NPs preparation methods and their importance in cancer therapy.
近几十年来,纳米医学研究取得了显著进展。然而,传统的纳米医学面临着一些重大障碍,如药物在靶部位的浓度低和药物从血液循环中加速清除。各种纳米技术技术,包括细胞膜涂层,已经被开发出来以应对这些挑战,并提高靶向分布和减少细胞膜介导的免疫原性。最近,由于具有免疫抑制和再生特性,干细胞(SC)膜作为靶向特定组织或器官的有吸引力的治疗载体引起了关注。由于具有归巢潜力和肿瘤趋向性,将合成纳米颗粒(NPs)与 SC 膜结合的生物工程策略最近受到了广泛关注。几项实验室实验和临床试验表明,基于 SC 的技术的益处主要与 SC 衍生的外泌体(SC-Exos)的作用有关。外泌体是已知的纳米级细胞外囊泡(EVs),可传递特定的生物活性分子以进行细胞间通讯。在这方面,最近已经使用 SC 衍生的外体膜来提高工程药物输送载体的治疗能力。最近,为了进一步提高 NPs 的功能,提出了一种新的涂层方法,该方法结合了来自两个不同细胞的膜。这些混合膜递送载体为开发具有不同混合能力的生物相容性、高效、仿生 NPs 铺平了道路,这些 NPs 可以克服现有基于 NP 的治疗技术的缺点。本文综述了干细胞膜、SC-Exos 和混合 SC 伪装 NPs 的制备方法及其在癌症治疗中的重要性。